

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



廣州白雲山醫葯集團股份有限公司

GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS CO., LTD.

(a joint stock company with limited liability established in the People's Republic of China)

(H Share Stock Code: 0874)

UPDATE ON THE PROPOSED PLACING

References are made to the circular of Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited (the “**Company**”) dated 26 February 2015 (the “**Circular**”) in relation to the Proposed Placing and the announcements of the Company in relation to the Proposed Placing issued subsequent to the Circular, the last of which being the announcement dated 26 November 2015. Unless otherwise defined, capitalised terms used in this announcement shall have the same meanings as those defined in the Circular.

The Issuance Examination Committee of the CSRC reviewed the application of the Proposed Placing on 9 December 2015. According to the review results, the Proposed Placing (as revised) has been approved.

As at the date of this announcement, the Company has not yet received written approval document(s) from the CSRC. The Company will make further announcement(s) as soon as practicable after the written approval document(s) from the CSRC have been received.

The Board of
Guangzhou Baiyunshan Pharmaceutical Holdings Company Limited

Guangzhou, the PRC, 9 December 2015

As at the date of this announcement, the board of directors comprises Mr. Li Chuyuan, Mr. Chen Mao, Ms. Liu Juyan, Ms. Cheng Ning, Mr. Ni Yidong, Mr. Wu Changhai and Mr. Wang Wenchu as executive directors, and Mr. Wong Lung Tak Patrick, Mr. Qiu Hongzhong, Mr. Chu Xiaoping and Mr. Jiang Wenqi as independent non-executive directors.